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Several mathematical and standard epidemiological models have been proposed in studying infectious disease dynamics. *ese
models help to understand the spread of disease infections. However, most of these models are not able to estimate other relevant
disease metrics such as probability of ﬁrst infection and recovery as well as the expected time to infection and recovery for both
susceptible and infected individuals. *at is, most of the standard epidemiological models used in estimating transition
probabilities (TPs) are not able to generalize the transition estimates of disease outcomes at discrete time steps for future
predictions. *is paper seeks to address the aforementioned problems through a discrete-time Markov chain model. Secondary
datasets from cohort studies were collected on HIV, tuberculosis (TB), and hepatitis B (HB) cases from a regional hospital in
Ghana. *e Markov chain model revealed that hepatitis B was more infectious over time than tuberculosis and HIV even though
the probability of ﬁrst infection of these diseases was relatively low within the study population. However, individuals infected
with HIV had comparatively lower life expectancies than those infected with tuberculosis and hepatitis B. Discrete-time Markov
chain technique is recommended as viable for modeling disease dynamics in Ghana.
1. Introduction
Tuberculosis (TB) is predominant among patients with
human immunodeﬁciency virus (HIV) according to the
WHO [1] report.*us, TB is considered as the main cause of
mortality among individuals susceptible to HIV [2]. *us,
the combined eﬀect of the two diseases is regarded as ex-
tremely fatal as compared to the individual or marginal eﬀect
of each of the underlying diseases on the individual. Ad-
ditionally, WHO [3] conﬁrmed that most HIV patients
contract tuberculosis as the ﬁrst evidence of AIDS, with
about 33.3% of 38.6 million HIV-positive patients world-
wide, also infected with tuberculosis, and are all at risk of
contracting fully TB disease. Among other possible means of
HBV infection spread, the dominant modes of transmission
for the high prevalence of the disease infection in the
community under study (Kumasi, Ashanti region) and its
surroundings are usually through transfusion of infected
blood, unprotected sexual activities, use of unsterilized
blades or barbering equipment, and mother-to-child
transmission during delivery [4]. On the other hand, HIV
spread is associated with sexual risk behavior among HIV-
positive individuals, which consequently put uninfected
persons at risk of HIV infection.
According to [5], out of 36 million HIV-infected in-
dividuals, approximately 4 million were found to have
chronic HBV.
*e immune system which is the body’s natural defense
system against pathogens, infections, and illnesses is made of
some special cells known as the CD4 cells. *ese underlying
cells are white blood cells that ﬁght against various forms of
infections in the human system and thus provide an over-
view of the performance of the immune system. Hence, the
count of CD4 cells in an individual at any time determines
the strength of his or her level of immunity. However, the
counts of CD4 cells are mostly aﬀected by viral and bacterial
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infections.*is explains why the combined eﬀects of any two
of these underlying diseases (HIV, TB, and HB) on an in-
dividual are extremely dangerous [6]. Consequently, these
diseases under consideration must be viewed as a public
health concern in Ghana and the world at large. Among
adults and adolescents in Ghana, the ﬁrst-line ARTregimens
prescribed comprises of a nonthymine nucleoside reverse
transcriptase inhibitors (tenofovir+ emtricitabine or teno-
fovir+ lamivudine) and one nonnucleoside reverse tran-
scriptase inhibitor normally efavirenz [7].
Several mathematical and standard epidemiological
models have been proposed in studying infectious disease
dynamics. *ese models help us to understand the spread
of disease infections. However, most of these models are
not able to estimate other relevant disease metrics such as
probability of ﬁrst infection and recovery as well as the
expected time to infection and recovery for both suscep-
tible and infected individuals. Most of the standard epi-
demiological models used in estimating transition
probabilities (TPs) are not able to generalize the transition
estimates of disease outcomes at discrete time steps for
future predictions. *is paper seeks to address the afore-
mentioned problems by adopting a discrete-time Markov
chain model as proposed in [8]. In this study, the nth-step
transition probability matrices for each disease are de-
termined using the ﬁrst-order Markov chain model. *e
ﬁndings would help policy makers to ascertain which of the
diseases under study are most infectious and deadly so that
measures could be put in place to reduce or minimize its
prevalence.
2. Materials and Methods
2.1. Source ofData. *e data used for the study were collected
from a regional hospital in Ghana since it serves as a major
referral center. Data were obtained fromperiodic follow-ups of
HIV, TB, and hepatitis B patients from January 2016 to
December 2016. Each patient was followed for a year irre-
spective of their entry times in the course of the year. Patients
with TB relapse or reinfection as well as patients with con-
ﬁrmed coinfections or other medical complications (and lost
to follow-up) were excluded or withdrawn for medical at-
tention. Among subjects susceptible (uninfected) to these
diseases after medical tests, counts of those who were found
infected and dead (or immune to the disease possibly) by the
end of the study period (till the last eligible subject was fol-
lowed for a year) were recorded. Similarly, among subjects
infected in the course of the study (after medical screening for
each disease), counts of those who recovered (TB only),
remained infected, and died were also recorded.
2.2. S-I-R Modeling by Markov Chain Process
2.2.1. Model Development. Consider three discrete states:
susceptible (state 0), infected (state 1), and removed (state 2)
states. If (Xi, i � 0, 1, 2) represent the number of individuals
at any state from the underlying diseases at any time t, then
clearly, Xi is a stochastic process with states 0, 1, and 2.
*us, the ﬁrst-order time-homogeneous Markov de-
pendency can statistically be modeled as
P Xn � in | Xn− 1 � in− 1, . . . , X1 � i1, X0 � i0( )
� P Xn � in | Xn− 1 � in− 1( ).
(1)
*en, the transition probability (Pij) for i, j � 0, 1, 2 is
denoted in matrix form as
Pij( ) �
P00 P01 P02
P10 P11 P12
0 0 1


, (2)
where
∑
2
j�0
Pij � 1, i � 0, 1, 2. (3)
2.2.2. Deﬁnition of States in the S-I-R Model
Susceptible state (S): it comprised of individuals who
have not been exposed before and individuals who have
recovered from an infection.
Infectious state (I): it comprised of infected individuals
and carriers of the disease.
Removed state (R): it comprised of individuals who
either died from the disease or were immune after
recovery from the diseases (HIV excluded) in the
course of the study period.
2.2.3. Parameters of the Markov Chain (Probabilities of
Transition)
Pii: probability of remaining in a state i.
Pij: transition probability from state i to state j, i≠ j.
Remarks. *e parameter P01 is mostly referred to in the
literature as discrete time force of infection. Also, the ele-
ments P02 and P12 signify mortality for uninfected and
infected individuals, respectively, while P10 is the recovery or
defection probability [9]. Death is an absorbing state since
the probability of becoming susceptible or infected is zero.
*e time step unit to ensure the transition from one state to
another is measured on a yearly basis.
2.3. Model Assumptions
*e current state of an individual is dependent only on
the state of the individuals at the previous time step.
No individual at the removed state can be susceptible or
infected.
Transitioning probabilities are independent of time and
remain constant over time or the study period.
Successive transitions or relapse conﬁrmed coin-
fections of the diseases or other medical complications
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were not taken into consideration or did not meet the
eligibility criteria of the study.
*e removed state comprised of subjects who either
died from the disease or found to be immune after
recovery.
*e only assumption required regarding losses and
withdrawals is that they have the same future experi-
ence as those remaining under observation.
2.4. Estimating Transition Probabilities. *e maximum-
likelihood estimation (MLE) was used to estimate the
transition probabilities for each disease with their respective
standard errors. Table 1 shows the number of individuals
during the study period at any state (S-I-R) for each cohort
study for the three diseases (HIV, TB, and HB).
Remarks. *e number of infected individuals who re-
covered at the end of the second stage or study period of the
cohort studies for both HIV and HB would be zero since
HIV and chronic hepatitis B are not curable as opposed to
TB, but can be treated. *ere exists a ﬁnite treatment, es-
pecially for many cases of hepatitis B.
*e transition events are independent of one another
(as deﬁned by the Markov principle); the likeli-
hood of the transition probability, Pij, follows a binomial
model:
L Pij | N, x( ) �
Ni
xij
 P
xij
ij 1 − Pij( )
Ni− xij
, (4)
where Nij is the number of observed transition that starts
from state i to j and
∑
j
Pij � 1. (5)
From equation (4) and the assumption of constant
transition probabilities over the period, the transition
probability matrix is estimated as a multinomial distribution
given as
P̂ij �
xij
∑jxij
�
xij
Ni
, (6)
for i, j � 0, 1, with standard errors from the sampling dis-
tribution of the ML estimate given as
ŝ.e Pij( ) �
����������
p̂ij 1 − p̂ij( )
Ni
√
√
. (7)
2.5. Estimating Disease Metrics. *e probability that a sus-
ceptible individual becomes infected for the ﬁrst time be-
tween m − 1 and m time steps for states i, j � 0, 1 from the
transition probability matrix (S-I-R) is given as
f
(m)
01 � P Xn+m � 1, Xn+m− 1 � 0, . . . , Xn+1 � 0 | Xn � 0( )
� P
m− 1
00 P01.
(8)
Similarly, the probability that an infected individual ﬁrst
recovers between m − 1 and m time steps is given as
f
(m)
10 � P Xn+m � 0, Xn+m− 1 � 1, . . . , Xn+1 � 1 | Xn � 1( )
� P
m− 1
11 P10.
(9)
*e expected time to infection and recovery has a closed-
form solution which is computed as
E τ1ij( ) �
∑
∞
m�1mf
m
ij
Pr(i⟶ j)
�
1
1 − Pii
,
(10)
for i, j � 0, 1, i≠ j, where the numerator, ∑ mfmij , is the
expected value of ﬁrst passage time from state i to state j and
the denominator
Pr(i⟶ j) � Pij1 − Pii (11)
is the overall probability or lifetime probability of tran-
sitioning from state i to state j [8].
*e life expectancies (Wi, i � 0, 1) for susceptible and
infected individuals can also be estimated using the fol-
lowing equation:
W � (I − Q)
− 1
×
1
1
( ), (12)
where I is a 2 × 2 identity matrix and
Q �
P00 P01
P10 P11
( ). (13)
2.6. Estimating Pn Transition Matrix. *e method for es-
timating the nth-step transition probability matrices for
each disease uses the eigenvalue and eigenvector ap-
proach as proposed by Bhat [10]. *e Pnij, i, j � 0, 1, 2
transition probability matrix was estimated for each disease
Table 1: Number of individuals at any state for cohort.
Groups Susceptible Infected Dead
Susceptible individuals X00 X01 X02
Infected individuals X10 X11 X12
X00: number of susceptible individuals who remained susceptible at the end
of the study period; X01: number of susceptible individuals who became
infected at the end of the study period; X02: number of susceptible in-
dividuals who either died or remained immune after recovery at the end of
the study period; X10: number of infected individuals who recovered at the
end of the study period; X11: number of infected individuals who remained
infected at the end of the study period; X12: number of infected individuals
who either died or remained immune after recovery at the end of the study
period.
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using a decomposition method that requires eigenvalues and
their corresponding eigenvectors. Hence, it can be estimated
using the decomposition below:
P
n
� QΛnQ− 1, (14)
where Q is 3 × 3 nonsingular matrix (X0, X1, X2) and
Xj, (j � 0, 1, 2) is the right eigenvectors corresponding to
the eigenvalues λj(j � 0, 1, 2). *us,
PXj � λjXj, (15)
Λn � λn0 0 00 λn1 0
0 0 λn2

. (16)
3. Results and Discussion
3.1. Markov Chain S-I-R Model. Suppose that the discrete
states of theMarkov chainmodel for the diseases (HIV, TB, and
HB) are susceptible (state 0), infected (state 1), and removed or
dead (state 2) states. Let (Xi, i � 0, 1, 2) represent the number
of individuals at any state from the underlying diseases at any
time twhich satisﬁes the ﬁrst-order time-homogeneousMarkov
dependency from equation (1). Clearly, Xi satisﬁes the Markov
chain model with state space S � 0, 1, 2{ }.
Tables 2–4 show the number of individuals within the
study population at states 0, 1, and 2 for HIV, TB, and HB,
respectively.
3.2. Estimating the Transition Probabilities for Each Disease.
*emaximum likelihood was used to estimate the transition
probability matrix for each disease. Tables 5–7 show the
estimates and conﬁdence intervals of the transition proba-
bilities for HIV, TB, and HB, respectively.
*e transition probability matrices for the diseases are,
respectively, presented as
(17)
3.3. Classiﬁcation of Model States Using Graph Algorithm.
A graph algorithm was used to represent the transition
probabilities for each disease so as to easily classify the states
into recurrent, transient, or absorbing. From Figure 1, it can
be concluded that states {0} and {1} are both transient states
Table 2: Number of individuals at any state for HIV at the end of
the period.
Groups Total Susceptiblestate
Infected
state
Removed
state
Susceptible 8132 7598 502 23
Infected 502 0 478 24
Table 3: Number of individuals at any state for TB at the end of the
period.
Groups Total Susceptiblestate
Infected
state
Removed
state
Susceptible 669 552 99 18
Infected 99 81 18 0
Table 4: Number of individuals at any state for HB at the end of the
period.
Groups Total Susceptiblestate
Infected
state
Removed
state
Susceptible 2929 2281 623 25
Infected 623 0 600 23
Table 5: ML estimates of transition probabilities for HIV.
Parameters Estimate SE 99% conf. interval
P00 0.93 0.00283 0.923–0.937
P01 0.06 0.00263 0.053–0.067
P02 0.01 0.00110 0.007–0.013
P11 0.95 0.00973 0.925–0.975
P12 0.05 0.00973 0.025–0.075
Table 6: ML estimates of transition probabilities for TB.
Parameters Estimate SE 99% conf. interval
P00 0.83 0.01452 0.793–0.867
P01 0.15 0.01381 0.114–0.186
P02 0.02 0.00541 0.006–0.034
P10 0.82 0.03861 0.721–0.919
P11 0.18 0.03861 0.081–0.279
Table 7: ML estimates of transition probabilities for HB.
Parameters Estimate SE 99% conf. interval
P00 0.78 0.00765 0.760–0.800
P01 0.21 0.00752 0.191–0.229
P02 0.01 0.00184 0.005–0.015
P11 0.96 0.00785 0.940–0.980
P12 0.04 0.00785 0.020–0.060
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for transitions with respect to HIV and hepatitis B. *is is
because, upon an individual leaving those states, there is no
positive probability of returning to its original state.
However, state {0, 1} is a transient class for transitions re-
garding tuberculosis since the two states have the same
equivalence class as well as communicates, but, upon an
individual leaving that class, there is no positive probability
of returning to that class. State {2} which is also known as the
removed state is an absorbing state for any disease transi-
tions since an individual at this state remains dead with a
certain probability of one. *erefore, it can be inferred from
the state classiﬁcations that the Markov chain is not ergodic.
*at is, even though the chain is aperiodic, it is not irre-
ducible since all the states do not belong to the same
equivalence class. Figure 1 shows a graphical representation
of the transition probabilities, respectively, for each disease.
3.4. Estimating Disease Metrics
3.4.1. Probability of First Transition. *e probability that a
susceptible individual becomes ﬁrst infected was estimated
for all the underlying diseases using equation (8). In ad-
dition, the probability that an infected individual ﬁrst
becomes susceptible or recovers was estimated for only
tuberculosis using equation (9) since HIV and hepatitis B
have no cases of recovery from infection. Figure 2 shows a
plot of ﬁrst transition probabilities across various time
steps from 1 to 50.
From Figure 2, it can be observed that the probability of
ﬁrst infection of the three underlying diseases within the
study population was relatively low (below 0.20). *is could
be due to the interventions (or medications) administered to
the study population to control the spread of these diseases
[11]. Moreover, it can also be inferred that, before the 10th
time step (in 10 years after the study period), the probability
of ﬁrst hepatitis B infection by a susceptible individual was
relatively higher, followed by tuberculosis infection and then
HIV infection. On the contrary, the probability of ﬁrst in-
fection after the 10th time step was comparatively higher
among HIV patients as opposed to both TB andHB patients.
*is ﬁnding is consistent with that obtained in [12], where
the majority of people exposed to HIV ﬁrst get infectious
after 10 years of exposure without treatment. Also, the
probability of ﬁrst recovery from tuberculosis was very high
at lower time steps but declined sharply across increasing
time steps. *us, it simply suggests that if a patient is di-
agnosed of TB at the early or latent stage, lasting control
measures can be put in place to ﬁrst recover from the disease.
*is is because most people with active TB after receiving
proper treatment for at least 2 weeks are no longer conta-
gious. However, if a TB patient is infected for a longer
period, then there is a relatively very small probability of
recovering from the disease in some future time steps.
3.5. Probability of Infection at Any Time Period. *e proba-
bility of infection at any time from the three underlying diseases
was estimated using the cumulative sum of the probabilities of
ﬁrst infection of susceptible individuals. Figure 3 is a plot of the
cumulative transition probabilities over time.
*e estimation of the probability of infection from the
ﬁrst transition probabilities as shown in Figure 3 revealed
that hepatitis B appeared to be more infectious over time
within the study population, followed by tuberculosis and
HIV infections, respectively. *is ﬁnding agrees with out-
comes from other health surveys. WHO [12] from their
studies over the years also found that even though the mode
of transmission of HIV and HB are similar, hepatitis B is
about 50 to 100 times more infectious than HIV. *is is
because HB virus unlike HIV can even live outside the host
for at least a week and still cause infection in a susceptible
individual as well as have a relatively higher rate of viral
incubation. In addition, blood levels associated with the
Transition for TBTransition for HIV Transition for HB
Figure 1: Directed multigraph of transitioning from one state to another.
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Figure 2: Probability of ﬁrst infection and recovery.
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HBV are relatively higher than for HIV, thereby causing this
virus to be easily transmitted in situations such as child
delivery (from mother to child) and even through body
ﬂuids, which cannot happen in the case of HIV transmission.
On the other hand, hepatitis B was also found to be more
contagious than tuberculosis since the probability of HB
infection at any time was relatively higher than TB spread.
Bacterial infections such as TB are mostly cured by antibiotic
drugs which are ineﬀective against viral infections such that
their infection dynamics can even be controlled unlike
hepatitis B at any stage of exposure. However, HIV seems
less infectious after ﬁrst infection comparatively and this
could be due to the fact that the virus ﬁrst attacks the
immune system of individuals which usually takes about 5 to
10 years to get it fully compromised even when left untreated
[12]. *us, individuals with very strong immune system
develop the infection at a relatively lower rate as opposed to
TB and HB infections which also aﬀects the immune system.
It was also revealed that the probability of infection of these
three diseases increases with increasing time period. *is
further suggests that HIV, TB, and HB get very infectious
with increasing time if left unattended. *is accounts for the
deadliness of these three diseases due to its high rate of
infection over the years. It also conﬁrms why the combined
eﬀect of any two of these diseases on an individual can be
extremely deadly as compared to the individual eﬀects on
persons suﬀering from either HIV, TB, or HB.
3.6. Other Estimated Disease Metrics
3.6.1. Overall Probability of Infection and Recovery.
Other disease metrics such as the overall probability of
infection and recovery were estimated using equation (11).
*e overall probability of infection for HIV, TB, and HB was
found to be approximately 0.86, 0.88, and 0.95, respectively.
*ese ﬁndings are consistent with results obtained from the
cumulative sums of the ﬁrst infection probabilities as pre-
sented by Figure 3, where HB was more infectious over time
as opposed to TB and HIV. Hence, it can be inferred that
hepatitis B was the most infectious disease during the study
period at the regional hospital. *e study also found that it is
certain to cure tuberculosis as opposed to HIV and HB
which are incurable at the infectious or chronic stage.
3.6.2. Assessing the Statistical Signiﬁcance of the Overall
Probability of Infection. *e statistical signiﬁcance of the
estimate of the overall probability of infection for each
disease from the Markov model was measured using
bootstrap interval estimation technique at 1% level of sig-
niﬁcance. Hence, it can be concluded with 99% level of
conﬁdence that the overall probability of infection for each
disease would fall in the estimated conﬁdence intervals as
summarized in Table 8.
3.7. Expected Time to Infection and Recovery. Also, the ex-
pected time to infection and recovery was estimated from
equation (10) for each disease.*e expected time to infection
by a susceptible individual was found to be 14.29 years, 5.88
years, and 4.55 years for HIV, TB, and HB infections, re-
spectively, within the cohort considered. *at is, an indi-
vidual exposed to HIV will on the average start experiencing
the infection after approximately 14.29 years even though
the length of time can vary widely between individuals. *is
ﬁnding aﬃrms that obtained in [12], where individuals
exposed to HIV fully developed the signs and symptoms of
the infection usually between 10 and 15 years. On the other
hand, the average time at which an individual exposed to TB
would become fully infectious if left untreated was estimated
as 5.88 years after exposure, whereas that of HB was esti-
mated as 4.55 years. Hence, it can be inferred that hepatitis B
infection develops faster on the average as compared to HIV
and tuberculosis infections over time.
On the contrary, TB was found to have an expected
recovery time of 1.22 years, whereas the expected time at
which the symptoms and signs of HIV and HB would have
been diminished was estimated as 20 years and 25 years,
respectively. However, the expected to recover from HIV
and hepatitis B as deﬁned for this study coincided with the
estimate of their respective life expectancies for infected
individuals using the Markov chain model. Hence, it can be
concluded that the life expectancy of an infected individual
with respect to HIV and HB is indeed the period beyond
which an infected individual recovers or dies.
3.8. Life Expectancy for Healthy and Infected Individuals.
Life expectancy, which is a statistical measure of the average
time an individual is expected to live or survive, was esti-
mated using equation (12) for both healthy and infected
individuals. Consequently, the life expectancy for healthy
individuals in the presence of HB, HIV, and TB was esti-
mated as 28.41 years, 31.43 years, and 59.15 years, re-
spectively. *ese estimates further revealed that in a
population where hepatitis B is prevalent, the average life
span of any healthy individual is relatively smaller as
compared to higher estimates obtained for a population
infected with HIV and TB, respectively. However, the life
expectancy for individuals infected with HIV, HB, and TB
was found to be 20 years, 25 years, and 60.37 years, re-
spectively. It implies that the average life span of HIV pa-
tients is relatively lower than that of HB and TB patients
even though they were found to be very infectious than HIV.
*is is because when the immune system of HIV patients
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Figure 3: Probability of infection over the years for infected
individuals.
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gets compromised over time, it creates a way for various
infections which takes advantage of the weakened immune
system such as tuberculosis and other comorbidities to aﬀect
the victim. Table 9 presents the estimates of other disease
metrics (probability of infection, expected time to infection/
recovery, and life expectancy for healthy/infected in-
dividuals) for HIV, TB, and HB.
3.9. Estimating the Pn Transition Probability Matrix. *e Pn
transition probability matrix was estimated from equation
(14). *e chain is aperiodic but not irreducible since the
removed state (2) was an absorbing state. *e Pn transition
probability matrix predicts the transition probabilities for
each disease at any time step.
Pn transition probability matrix for HIV is estimated as
P
n
HIV �
0.93n 3 0.95n − 0.93n( ) 1 − 3 0.95n( ) + 2 0.93n( )
0 0.95n 1 − 0.95n
0 0 1

.
(18)
Clearly, n � 1 from the estimated Pn transition matrix
gives the actual ﬁrst transition matrix PHIV. *erefore, the
transition matrix at any time step (n≥ 1) can be generated
from the ﬁtted Pn matrix.
Also, estimated n-step transition matrix for TB is given as
P
n
TB �
0.8 0.9831n( ) + 1.6 0.0269n( ) 0.16 0.9831n − 0.0269n( ) 1 − 0.9831n − 0.0032 0.0269n( )
0.86 0.9831n − 0.0269n( ) 0.16 0.9831n( ) + 0.84 0.0269n( ) 0
0 0 1

. (19)
Clearly, n � 1 from the estimated Pn transition matrix
(in 2 d.p.) gives the actual ﬁrst transition matrix PTB.
Finally, the n-step transition probability for hepatitis B is
given as
P
n
HB �
0.78n 1.17 0.96n − 0.78n( ) 1 − 1.17 0.96n( ) + 0.17 0.78n( )
0 0.96n 1 − 0.96n
0 0 1

.
(20)
Also, considering n � 1 from the estimated Pn (in 2 d.p.)
transition matrix gives the ﬁrst transition matrix PHB.
4. Conclusion and Recommendation
*eMarkov chain model revealed that hepatitis B was more
infectious over time than tuberculosis and HIV within the
study population (2016 cohort at the regional hospital) al-
though the probabilities of ﬁrst infection of these diseases
were relatively low. However, individuals infected with HIV
had relatively lower life expectancies than those infected
with TB and HB. *e Markov chain model is therefore
recommended as a viable technique in estimating other
relevant epidemiological quantities of infectious diseases as
well as generalizing the transition probabilities for future
predictions.
Data Availability
*e Microsoft Excel Worksheet data used to support the
ﬁndings of this study are available from the corresponding
author upon request.
Conflicts of Interest
*e authors declare that they have no conﬂicts of interest.
References
[1] WHO, “WHO—tuberculosis and HIV,” WHO, 2019, https://
www.who.int/tb/features{_}archive/.
[2] A. Zumla, A. George, V. Sharma, R. H. N. Herbert, A. Oxley,
and M. Oliver, “*e WHO 2014 global tuberculosis report-
further to go,” =e Lancet Global Health, vol. 3, no. 1,
pp. e10–e12, 2015.
[3] WHO, “WHO—WHA approves post-2015 global TB strategy
and targets,” WHO, 2015, https://www.who.int/tb/features{_}
archive/globaltb{_}strategy/en/.
Table 8: Estimated bootstrap conﬁdence intervals.
Overall probability
of infection
Markov chain
estimate SE
99% conf.
interval
HIV 0.86 0.00385 0.84981–0.86977
Tuberculosis 0.88 0.01218 0.84753–0.91226
Hepatitis B 0.95 0.00397 0.93979–0.96005
Table 9: Estimates of other disease metrics for each disease.
Metrics HIV Tuberculosis HepatitisB
Overall probability of infection 0.86 0.88 0.95
Overall probability of recovery — 1.00 —
Expected time to infection
(years) 14.29 5.88 4.55
Expected time to recovery
(years) 20.00
∗ 1.22 25.00∗
Life expectancy for healthy
individuals (years) 31.43 59.15 28.41
Life expectancy for infected
individuals (years) 20.00 60.37 25.00∗Expected time to recovery from HIV and TB is also known as life ex-
pectancy for infected individuals.
Interdisciplinary Perspectives on Infectious Diseases 7
[4] R. Ofori-Asenso and A. A. Agyeman, “Hepatitis B in Ghana: a
systematic review & meta -analysis of prevalence studies
(1995–2015),” BMC Infectious Diseases, vol. 16, no. 1, p. 130,
2016.
[5] V. Soriano, M. Puoti, M. Peters et al., “Care of hiv patients
with chronic hepatitis b: updated recommendations from the
HIV-hepatitis B virus international panel,” Aids, vol. 22,
no. 12, pp. 1399–1410, 2008.
[6] M. Puoti, C. Torti, R. Bruno, G. Filice, and G. Carosi, “Natural
history of chronic hepatitis B in co-infected patients,” Journal
of Hepatology, vol. 44, pp. S65–S70, 2006.
[7] NACP, Ghana ART guidelines-2016.Pdf, NACP, New Delhi,
India, 2016.
[8] E. F. Zipkin, C. S. Jennelle, and E. G. Cooch, “A primer on the
application of Markov chains to the study of wildlife disease
dynamics,” Methods in Ecology and Evolution, vol. 1, no. 2,
pp. 192–198, 2010.
[9] J. E. Cohen, “Selective host mortality in a catalytic model
applied to schistosomiasis,”=e American Naturalist, vol. 107,
no. 954, pp. 199–212, 1973.
[10] U. N. Bhat, Elements of Applied Stochastic Process, vol. 2, John
Wiley & Sons, Hoboken, NJ, USA, 2nd edition, 1984.
[11] S. I. Shalaby, “HIV/AIDS and CAM,” Sryahwa Publications,
Lewes, DE, USA, 2018, http://www.ijrsmhs.com/pdf/v3-i4/2.
pdf.
[12] WHO, Consolidated Guidelines on the Use of Antiretroviral
Drugs for Treating and Preventing HIV Infection: Recom-
mendations for a Public Health Approach, World Health
Organization, Geneva, Switzerland, 2016.
8 Interdisciplinary Perspectives on Infectious Diseases
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
